**Background**
==============

Previous studies have described four immunopathological patterns of demyelination in early multiple sclerosis (MS) lesions, with pattern II being characterized by antibody and/or complement-associated demyelination \[[@B1]\]. Several specific antibodies have been described and discussed to contribute to the humoral autoimmune response in MS \[[@B2]\]. Immunoglobulins are synthesized intrathecally; however, at least part of the humoral response in MS is derived systemically from the blood \[[@B3]\].

Therapeutic plasma exchange (PE) is based on the separation of plasma from cellular blood components, allowing the removal of substances up to a molecular weight of 3 × 10^3^ kDa. As shown in a randomized placebo controlled cross-over study, PE was efficient for steroid - refractory relapses in about 40% to 50% of cases of acute central nervous system inflammatory demyelinating diseases \[[@B4]\]. The usefulness of PE has also been extended to severe optic neuritis in patients with MS \[[@B5],[@B6]\]. Thus, the use of PE in steroid-refractory relapses has become an integral part of European guidelines for the treatment of MS \[[@B7]\]. Clinical-pathological correlation analyses have shown that all patients with pattern II pathology but none with pattern I or pattern III experienced improvement in neurological deficits after being treated with PE \[[@B8]\]. This selective response suggests a removal of pathogenic humoral and plasma factors by PE.

Immunoadsorption (IA) provides a more selective approach and the potential for technical innovations in therapeutic apheresis techniques, allowing the elimination of pathogenic antibodies while sparing other plasma proteins. With IA, relevant side effects of PE resulting from protein substitution can be avoided \[[@B9]\]. We hypothesized that IA is at least equally efficient compared to PE as an escalation therapy for steroid-unresponsive relapses of MS. Therefore, we performed a prospective trial to compare IA treatment in 11 patients with MS with our earlier patient population treated with PE for their MS \[[@B10]\]. In addition, proteomic analyses of column-bound proteins were performed as well as measurements of corresponding changes in patients' plasma samples.

**Methods**
===========

**Patients**
------------

We prospectively included 11 consecutive patients with MS who had functionally disabling acute optical neuritis. Patients fulfilled the indications for apheresis treatment due to this steroid-unresponsive MS relapse according to German guidelines (<http://www.dgn.org>) \[[@B7]\].

The study protocol had been approved by the local ethics committee prior to study initiation (no. 2/4/07) and registered at the local government (no. DE/CA25/00007080-00). All patients gave their written informed consent before enrolment.

**Immunoadsorption treatment**
------------------------------

IA was performed using the tryptophan-linked polyvinyl alcohol adsorber TR-350, after membrane plasma separation with the polyethylene plasma separator OP-05 W (Asahi Kasei Kuraray, Tokyo, Japan) in combination with the Octo Nova extracorporeal circuit technology (SW 4.30.2, front 4.30.0) (Diamed Medizintechnik, Cologne, Germany). The adsorber, plasma separator and tubing system were for single use only. Combined anticoagulation, with citrate and unfractionated heparin, was used for all treatments. The treated plasma volume was 2,500 mL plasma for all treatments of all patients. In total, five sessions were performed in each patient on alternate days. In case of complications or decrease of fibrinogen below 100 mg/dL, treatment-free intervals were extended individually. Internal jugular veins were used for central vascular access with double lumen catheters in all patients.

**Baseline and follow-up visits**
---------------------------------

All patients were followed up by a neurologist. Visits were performed at baseline (visit 0), after each IA treatment (visits 2 to 5) and after 30 ± 5 days (visit 6), 60 ± 10 days (visit 7) and 180 ± 10 days (visit 8). The neurological findings were assessed using the Expanded Disability Status Scale (EDSS) and the Incapacity Status Scale (ISS) \[[@B11]-[@B13]\]. Changes of visual acuity were monitored using standardized near vision types after correction of refractive error at each visit and confirmed by an ophthalmologist before and after IA, as well as at 180 ± 10 days. Visual evoked potentials were determined at baseline, after the last IA and 60 ± 10 days post-intervention with the Neuropack M1 (Nihon Koden, Surbiton, UK).

**Classification of side effects**
----------------------------------

Side effects were defined as any unexpected or symptomatic event that had a possible, probable or definite causal relationship with IA treatment \[[@B14]\]. They were classified as mild, moderate or severe as described previously \[[@B15]\] with small modifications. Briefly, mild side effects included those of transient nature with little or no clinical significance and without any temporary break of the procedure. Side effects that required medical intervention but were not life-threatening were classified as moderate. Unstable and life-threatening events requiring termination of the procedure were classified as severe.

**Clinical chemistry**
----------------------

All laboratory parameters were measured by standard methods. The complement components C3c and C4 as well as the immunoglobulins G (IgG), A (IgA) and M (IgM) were measured by nephelometry (Behring Nephelometer II Analyzer, Germany). Soluble interleukin-2 receptor (sIL-2R) was detected on an immulite system (Siemens, Germany).

**Identification of immunoadsorption column-binding proteins by elution and proteomics**
----------------------------------------------------------------------------------------

Immusorba TR-350 column-binding proteins were eluted after the first IA treatment in five of eleven patients. Prior to elution, the column was washed with PBS buffer. The protein elution was carried out as following: PBS-washing step was followed by a three-step elution protocol using solution A (100 mM sodium acetate, 1 M NaCl, pH 5), solution B (20 mM Tris--HCl, 1 M NaCl, pH 8.5) and solution C (20% acetonitril in double diluted H2O). Proteins eluted from all three steps were pooled together and aliquots of 10 mL were used for protein precipitation, protein estimation and two-dimensional gel electrophoresis.

Two-dimensional gel electrophoresis, protein visualization and image analysis, in-gel digestion, mass spectrometry analysis of the digestion products and protein identification using a database search were performed as described in detail in our previous publication \[[@B16]\]. For protein identification, qualitative criteria encompassed optimized mass accuracy (\<50 ppm), minimal mass deviation (in the millidalton range) and highest possible probability score, which were assigned to each identified protein. Proteins identified by mass spectrometry are described qualitatively.

**Western blot analysis**
-------------------------

Western blot analyses were performed according to previously published data \[[@B17]\] with 20 μg of plasma proteins. Equal loading was ascertained by Coomassie staining. For immunodetection of proteins, the following antibodies were used: rabbit polyclonal to human CD5 ligand (CD5L) and mouse monoclonal to human myelin basic protein (both Abcam, Cambridge, UK); and horseradish peroxidase-linked donkey anti-rabbit antibody (Amersham Biosciences, Freiburg, Germany). Results are expressed as mean ± SD.

**Statistics**
--------------

Visit and response effects were studied by two-way repeated measures analysis of variance using the mixed procedure for the software SAS (version 9.1, SAS Institute). In this global analysis, *P* \< 0.05 indicated a significant effect. In the case of a significant effect at a particular visit, subsequent pairwise comparisons to baseline values were performed using one-way repeated measures analysis of variance to detect the point in time when the effect occurred. These comparisons were performed at Bonferroni-adjusted significance levels (related *P*-values are labeled with either Bonf. sig. (significant) or with Bonf. n.s. (non-significant)).

Smoothing splines with three degrees of freedom were fitted to mean values of each visit to illustrate the trends and the potential interactions between visits and response effects. Fitting was performed using the free software R (version 2.8, <http://www.r-project.org>).

Comparative statistical analyses of changes within-subject and within-treatment were performed using *t*-tests for paired samples in case of normal data and Mann--Whitney *U*-tests for non-normal data. Normality was checked by quantile-quantile plots. Again, test results with *P \<* 0.05 were considered significant.

**Results**
===========

IA treatments were started after a mean time of 26.6 days after the initial symptoms and 10.8 days after the start of corticosteroid therapy. Each patient received at least two courses of corticosteroid therapy prior to IA therapy, with a mean cumulative dose of 10.9 g prednisolone equivalent but without a significant improvement, thus fulfilling the indication of therapeutic apheresis as adjunct treatment. An improvement of visual acuity up to 0.6 or more was achieved in eight of eleven patients (72.7%) undergoing IA treatment (responder group). Two patients did not respond to therapy at any time point and one patient improved during IA therapy but deteriorated shortly after the end of IA therapy, associated with the incidence of a jugular venous thrombosis on the same side (non-responder group). The relevant data of patients' characteristics are shown in Table [1](#T1){ref-type="table"}.

###### 

Clinical baseline characteristics of the participants

  **Parameter**                                            **Total (n = 11)**   **Responder (n = 8)**   **Non-responder (n = 3)**
  -------------------------------------------------------- -------------------- ----------------------- ---------------------------
  Gender                                                                                                 
  * Female*                                                7 (64%)              5 (62%)                 2 (67%)
  * Male*                                                  4 (36%)              3 (38%)                 1 (33%)
  Age                                                      33.6 ± 10.5          29.6 ± 9.2              44.3 ± 8.0
                                                           (19.0 to 55.0)       (19.0 to 47.0)          (39.0 to 55.0)
  Body mass index                                          25.5 ± 3.0           22.9 ± 2.6              26.2 ± 4.0
                                                           (20.1 to 30.7)       (22.0 to 30.7)          (20.1 to 25.7)
  Relapse rates in the past 12 months (median and range)   2                    2                       1
                                                           (1 to 4)             (1 to 4)                (1 to 2)
  Baseline Expanded Disability Status Scale                4                    3.5                     4
                                                           (2 to 7.5)           (2 to 7.5)              (3 to 4)
  Days after onset of relapse                              26.6 ± 14.6          29.3 ± 15.6             19.3 ± 10.1
                                                           (10.0 to 60.0)       (10.0 to 60.0)          (10.0 to 30.0)
  Days after initiation of corticosteroid therapy          10.8 ± 6.9           12.3 ± 6.6              7.0 ± 7.2
                                                           (1.0 to 20.0)        (3.0 to 20.0)           (1.0 to 15.0)
  Cumulative dose of prednisolone equivalents (g)          9.5 ± 3.7            8.6 ± 3.7               12.0 ± 2.6
                                                           (4.0 to 15.0)        (4.0 to 15.0)           (10.0 to 15.0)
  Duration of disease (years)                              3.5 ± 4.9            5.7 ± 2.9               2.7 ± 9.0
                                                           (0.0 to 16.0)        (0 to 7.0)              (0.0 to 16.0)
  Initial disease modifying therapy                        3 (27.3%)            2 (25%)                 1 (33.3%)
   Interferon beta                                         2 (18.2%)            2 (25%)                 0 (0%)
   Glatiramer acetate                                      1 (9.1%)             0 (0%)                  1 (33.3%)

Descriptive values are shown either as absolute numbers (frequencies) or mean ± standard deviation (minimum --maximum), except for baseline EDSS and relapse rates which are shown as medians and ranges.

**Visual acuity**
-----------------

Mean visual acuity of all patients significantly improved with a baseline value of 0.12 ± 0.12 before the start of IA, 0.36 ± 0.33 (*P* = 0.0234) after the third IA and 0.72 ± 0.38 (day 180 ± 10 after IA; *P* \< 0.001). The effect was even more pronounced in the responder group. Mean visual acuity before start of IA was 0.15 ± 0.12 with an increase after the third IA to 0.47 ± 0.32 (*P* = 0.0252 Bonf. n.s.) and even more up to 0.89 ± 0.15 (*P* \< 0.0001 Bonf. sig.) at day 180 ± 10 after IA. By contrast, in the non-responder group, no significant changes of visual acuity were detectable. Results are summarized in Figure [1](#F1){ref-type="fig"}.

![**Time-course of visual acuities of the affected eyes assessed by standard charts in 11 patients with multiple sclerosis treated by immunoadsorption.** Visual acuities were shown as box plots (outliers marked as X) at baseline (visit 0), after three IA therapies (visit 3), after five IA therapies (visit 5), after 30 days (visit 6), after 60 days (visit 7), and after 180 days (visit 8). Three patients did not show long-term improvement of visual acuity, they were termed non-responders in this study (shown as filled circles, partially overlapping each other). AE: affected eyes; sign.: significant (pairwise comparison to baseline).](1742-2094-9-80-1){#F1}

Relief of visual impairment inversely correlated with the time interval between the start of symptoms and the beginning of IA therapy (r = -0.539) with a trend (*P* = 0.08) favoring positive clinical response in early opposed to late IA initiation.

**Visual evoked potentials**
----------------------------

Before IA treatment, visual evoked potentials could not be identified in six of our patients with MS due to the severity of the optical neuritis. However, after treatment in four of these participants, potentials recovered at day 60. In five patients, the visual evoked potential amplitudes as well as latencies before and after IA could be compared. The mean amplitude was 2.31 ± 2.57 mV at baseline, 3.34 ± 2.60 mV after the last IA, and 5.69 ± 1.76 mV at day 60 (*P* = 0.37). Latencies did not show recovery in those five patients from baseline (107.6 ± 21.7 ms) until day 60 ± 10 (112.3 ± 17.1 ms).

**Expanded disability status scale and incapacity status scale**
----------------------------------------------------------------

The EDSS continuously improved in the responder group starting from 4.06 ± 1.82 at baseline to 3.44 ± 2.38 after the last IA to a minimum of 2.81 ± 2.72 at day 60 ± 10 (*P* = 0.58), in contrast to the non-responder group who showed no changes. However, EDSS is clearly dominated by ambulation \[[@B12]\] and rather insensitive for visual dysfunction \[[@B13]\]. In parallel, ISS ameliorated in the responder group from 8.00 ± 9.02 at baseline with a continuous decrease to a minimum of 5.75 ± 6.78 at day 180 ± 10 (*P* = 0.04), in contrast to no significant changes in the non-responder group.

**Side effects**
----------------

In total, 55 IA treatments were analyzed. Mild side effects were often reported and caused slight discomfort to the patients, such as coldness, cough, dizziness, headache, temporary hypertension, lacrimation, muscular cramps, nausea, palpations, pruritus, paresthesia, rhinorrhea, sweating, tinnitus or vomiting. They were transient and could be easily managed without therapy.

Ten moderate side effects were recorded during the IA phase. These included vascular access problems such as central venous catheter infection and jugular venous thrombosis as well as therapy-associated events that included chest pain, dyspnoe, transient hypotension and urticaria, which could be easily managed by approved medical interventions. Two patients developed febrile infections (common cold and phlebitis of a peripheral vein) within 24 h of IA, which were possibly related to short-term immune dysfunction caused by corticosteroid therapy and IA. No severe side effects occurred. Results are summarized in Table [2](#T2){ref-type="table"}.

###### 

Moderate adverse events occurring during immunoadsorption that were classified as being related to vascular access, the immunoadsorption procedure or immunosuppression

                                                                                      **Patients (n = 11)**   **Immunoadsorption therapies (n = 55)**
  ----------------------------------------------------------------------------------- ----------------------- -----------------------------------------
  **Vascular access-related**                                                                                 
  Central venous catheter exit site infection                                         1 (9.1%)                1 (1.8%)
  Jugular vein thrombosis                                                             1 (9.1%)                1 (1.8%)
  **Side effects during immunoadsorption therapy**                                                            
  Chest pain                                                                          1 (9.1%)                1 (1.8%)
  Dyspnoe                                                                             1 (9.1%)                1 (1.8%)
  Transient hypotension                                                               4 (36.5%)               5 (9.1%)
  Urticaria                                                                           1 (9.1%)                1 (1.8%)
  **Putatively related to immunosuppression both by steroids and immunoadsorption**                           
  Febrile infection                                                                   2 (18.2%)               2 (3.6%)

**Laboratory data**
-------------------

In routine analyses, no significant changes were seen for the following values: partial thromboplastin time, hemoglobin, hematocrit, thrombocytes, sodium, calcium, creatinine, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyltransferase, creatine kinase and C-reactive protein. Significant changes were detected for fibrinogen, leukocytes and total protein. Increased leukocyte counts at baseline were likely caused by corticosteroid therapy before starting IA.

Immunoglobulins IgA, IgG and IgM as well as complement components C3c and C4 significantly decreased during IA therapy (*P* \< 0.01). After the end of IA, however, these parameters gradually recovered and increased beyond baseline values (as shown for IgG and C3c in Figure [2](#F2){ref-type="fig"}A, B). We found a significant decrease of sIL-2R at a rate of -35.4 ± 20.7% (*P* = 0.0054) after just one IA session in our patients with MS. Furthermore, time-courses of sIL-2R in responders and non-responders showed a significant difference (*P* = 0.03; Figure [2](#F2){ref-type="fig"}C). Sample dilution in the patients' circulation due to IA was excluded by laboratory follow-ups of hematocrit and albumin in serum.

![**Clinical chemistry.** Time-courses of (**A**) IgG; (**B**) C3c and (**C**) sIL-2R. sIL-2R is shown in responders (blue) and non-responders (red). Box plots: sign: significant (pairwise comparison to baseline).](1742-2094-9-80-2){#F2}

**Proteomic data**
------------------

Our proteomic investigation allowed the identification of 41 proteins with a peptide mass fingerprinting-score \>65 in eluates of IA columns. We could identify apolipoproteins, hemorheologically relevant proteins, immunologically relevant proteins, myelin-related proteins and others. A representative two-dimensional gel is shown in Figure [3](#F3){ref-type="fig"}A and results are summarized in Table [3](#T3){ref-type="table"}.

![**Protein pattern of the eluate from the tryptophan column after the first immunoadsorption treatment in a single patient analyzed by two-dimensional gel electrophoresis.** (**A**) The protein spots were visualized by Flamingo fluorescence staining. (**B**) Time-course of plasma myelin basic protein fragment (molecular mass approximately 21 kDa) and soluble CD5L levels determined by western blot from a single patient with MS (upper panels) and densitometric analyses with baseline values set to 100% in the plasma of all 11 treated patients with MS before, during and after IA (lower panels). sign: significant (pairwise comparison to baseline).](1742-2094-9-80-3){#F3}

###### 

List of identified proteins from immunoadsorption column elutes pooled from five patients with multiple sclerosis after the first immunoadsorption therapy

  **Protein name**                                                  **Gene name**   **UniProt**   **SwissProt**   **Nominal mass**   **PMF-score**
  ----------------------------------------------------------------- --------------- ------------- --------------- ------------------ ---------------
  Alpha-1-antitrypsin                                               SERPINA1        A1AT HUMAN    57.5            46878              94
  Apolipoprotein A-I                                                APOA1           APOA1 HUMAN   56.6            30759              152
  Apolipoprotein A-IV                                               APOA4           APOA4 HUMAN   56.6            45371              67
  CD5 antigen-like                                                  CD5L            CD5L HUMAN    56.8            39603              120
  Cleavage stimulation factor, subunit, tau variant                 CSTF2T          CSTFT HUMAN   57.2            64624              57
  Clusterin                                                         CLU             CLUS HUMAN    56.8            53031              160
  Complement C1r                                                    C1R             C1R HUMAN     57.5            81606              72
  Complement factor I                                               CF1             CFA1 HUMAN    56.8            68072              86
  Complement factor H                                               CFH             CFAH          57.1            143680             61
  Complement factor H-related protein 2                             CFHR2           FHR2 HUMAN    57.4            30631              60
  Complement C4-A                                                   C4A             CO4A          57.4            192650             213
  Fibrin alpha C term fragment                                                      gi 223057     NCBI nr         14443              85
  Fibrinogen alpha chain                                            FGA             FIBA HUMAN    57.1            95656              103
  Fibrinogen beta chain                                             FGB             FIBB HUMAN    57.1            56577              170
  Fibrinogen gamma chain                                            FGG             FIBG HUMAN    57.2            52106              146
  Gelsolin                                                          GSN             GELS HUMAN    57.2            86043              95
  Histidine-rich glycoprotein                                       HRG             HRG HUMAN     57.0            60510              152
  Huntingtin-associated protein 1                                   HAP1            HAP1 HUMAN    57.5            76208              65
  Kininogen 1                                                       KNG1            KNG1 HUMAN    56.8            72996              96
  Transthyretin                                                     TTR             TTHY HUMAN    56.6            15991              89
  Immunoglobulin alpha-1 chain C region                             IGHA1           IGHA1 HUMAN   57.4            37631              130
  Immunoglobulin lamda chain C region                               IGLC1           LAC HUMAN     57.4            11230              218
  Immunoglobulin mu chain C region                                  IGHM            IGHM HUMAN    57.4            49960              90
  Immunoglobulin kappa constant protein                                             gi 49258112                   25915              78
  Immunoglobulin kappa chain, C region                              IGCK            IGCK HUMAN    57.2            11773              287
  Immunoglobulin kappa light chain variable region                                  gi 48475436   NCBI nr         21251              80
  Immunglobulin kappa light chain VLJ region                                        gi 21669479   NCBI nr         29086              76
  Inter-alpha-trypsin inhibitor                                     ITIP            ITIH4 HUMAN   57.5            103521             67
  Monoclonal immunoglobulin M antibody light chain                                  gi 41388186   NCBI nr         26008              65
  Microtubule-actin crosslinking factor 1                           MACF            MACF1         57.0            623626             57
  Mps one binder kinase activator-like2A                            MOBKL2A         MOL2A         57.0            25676              55
  Myelin basic protein                                              MBP             MBP HUMAN     56.6            33097              55
  Malate dehydrogenase cytoplasmic                                  MDH1            MDHC HUMAN    56.6            36631              57
  Plasminogen                                                       PLG             PLMN HUMAN    56.6            93247              89
  Serum albumin                                                     ALB             ALBU HUMAN    57.5            71317              101
  Serum amyloid P-component                                         APCS            SAMP HUMAN    57.5            25485              68
  Small ubiquitin-related modifier                                  SUMO1           SUMO1 HUMAN   57.2            11607              59
  Transmembrane and tetratricopeptide repeat-containing protein 1   TMTC1           TMTC1 HUMAN   57.2            88209              62
  Zinc finger protein basonuclin-2                                  BNC2            BNC2 HUMAN    57.2            1236677            62
  Zinc fincer protein 706                                           ZNF706          ZN706 HUMAN   57.4            8606               64
  39 S ribosomal protein L13 mitochondrial                          MRPL13          RM13 HUMAN    57.0            20736              58

Gene names, accession number and identification score are given. PMF: peptide mass finger printing.

Amongst all identified proteins, soluble CD5L and the myelin basic protein (MBP) fragment were quantitatively analyzed in patients' sera by western blots using specific antibodies (Figure [3](#F3){ref-type="fig"}B). The baseline value was set to 100% and follow-up values were given in percent of baseline. Plasma MBP levels significantly decreased during the first IA session to 46.4 ± 15.0% (*P* \< 0.001) and remained low even in the post-IA control at day 60 ± 10. In parallel, soluble CD5L (sCD5L) levels decreased to 50.5 ± 15.0% (*P* \< 0.001) after the first IA and remained subsequently low. Time-courses of sCD5L and MBP are shown in Figure [3](#F3){ref-type="fig"}B.

**Discussion**
==============

PE is an efficient treatment in acute central nervous system inflammatory demyelinating diseases \[[@B4]\], including severe optic neuritis, motor impairment or ataxia \[[@B5],[@B6]\] after steroid-refractory relapses, successful in about 40% to 50% of cases. Here, we report on the first prospective investigation of tryptophan-IA in 11 relapsing MS patients with optic neuritis refractory to corticosteroid pulses in an open prospective study. Overall, eight of eleven patients (72.7%) achieved a remission. One patient gradually improved but deteriorated again along with the development of jugular venous thrombosis, and two patients did not respond at all. The response to IA seems to be comparable to the best results achieved in PE series \[[@B5],[@B6]\] and to two very recent retrospective analyses of the effect of IA in steroid-refractory MS cases \[[@B18],[@B19]\]. As in our own PE study \[[@B10]\], significant clinical improvement was seen after the third extracorporeal treatment session with a trend in favor of early IA initiation compared to delayed IA initiation. Our treatment protocol was limited to a total of five IA sessions. Additional experience showed that increasing the number of apheresis sessions did not correlate with further improvement of outcome (data not shown). This observation is in accord with results of IA in acute autoimmune neuropathies like Guillain-Barré Syndrome \[[@B20]\].

Most side effects were typical of any apheresis procedure using central venous lines as vascular access, but not characteristic of IA. Compared with the safety data from previously published PE studies \[[@B15],[@B21]\], the incidence of mild adverse events was higher in our study, and moderate side effects were slightly more frequent. However, moderate side effects were almost level with our own study of neurological patients treated with PE \[[@B15]\]. Potential side effects of PE known to be related to the substitution of human plasma products were completely avoided \[[@B12]\].

Apart from clinical data, we analyzed possible therapeutic effects of IA with the help of proteomic analyses. Several relevant proteins, particularly fibrinogen and the immunoglobulins, were monitored. The decrease of fibrinogen is one limiting factor in the use of tryptophan-IA that makes regular controls necessary. Our protocol with five IA sessions on alternate days did not decrease fibrinogen to critical levels. Moreover, immunoglobulin depletion along with prior corticosteroid pulse therapy reflects a strong immunosuppression, which makes close controls of clinical and laboratory infection signs necessary. Previous investigations reported that the restoration of serum IgG levels until day 5 after IA does not result from increased antibody synthesis, but is probably related to changes of catabolism and immunoglobulin backflow \[[@B7]\]. Interestingly enough, we found a significant immunoglobulin increase beyond baseline values until day 180 ± 10 after the start of IA, suggesting additional mechanisms other than backflow alone.

Several mechanisms of PE action in neuroimmunological disorders have been described, such as a removal of pathogenic autoantibodies, a redistribution of pathogens from the extravascular to the intravascular compartment, increased proliferation of immune cells, an enhanced production of immunoglobulins, a promotion of suppressor T-cell function, and a deviation of cytokine patterns redressing a disturbed T-helper type 1 and T-helper type 2 balance \[[@B3]\]. Although IA has been termed specific, several studies have demonstrated additional binding properties of ligands other than immunoglobulins alone \[[@B22],[@B23]\]. According to our proteomics data, several proteins that are possibly involved in MS pathogenesis are removed from the plasma by IA, for example, transthyretin \[[@B24]\], serum amyloid P \[[@B24]\], complement factors \[[@B24]\], clusterin \[[@B24]\], gelsolin \[[@B24]\], kininogen-1 \[[@B24]\], MBP \[[@B25],[@B26]\], CD5L \[[@B27]\] and immunoglobulins \[[@B1],[@B3],[@B8]\]. We confirmed a decrease of serum levels by IA in two of them, MBP and sCD5L. MBP-like material has been detected in several body fluids including cerebral spinal fluid and the urine of patients with MS \[[@B28]\]. Since MBP and other myelin proteins have been shown to be encephalitogenic in animal models of MS, they could drive the systemic autoimmune response in patients with MS. Other investigations have demonstrated the prevalence of MBP-specific memory B-cells in the peripheral blood of relapsing patients with remitting MS that might prime T-cells in lymphoid organs to migrate into the central nervous system and to elicit IFN-γ secretion \[[@B25]\]. These data were further corroborated with the evidence of MBP-reactive T-cells among IL-2 expanded lymphocytes in patients with MS \[[@B26]\]. Thus, removal of MBP from the plasma by IA might interrupt these autoimmune mechanisms, although more research in this hypothesis is definitely needed.

sIL-2R, a marker of T~H~1 cell activation, is increased in the serum of patients with relapsing MS \[[@B14]\]. We induced a significant decrease of sIL-2R after IA in responders, but not in non-responders. Decreased sIL-2R levels might reflect the silencing of cellular autoimmune responses effective only in responders.

**Conclusions**
===============

Our clinical results show a high clinical efficacy of tryptophan-IA comparable to PE in the treatment of MS relapses refractory to corticosteroids. Furthermore, our experimental data suggest several possible effects on MS pathogenesis: not only removal of immunoglobulins and complement from plasma, but also reduced levels of circulating autoantigens and regulatory proteins. We suggest that more prospective studies are needed to confirm and extend our results, to give new insights into this treatment approach, to optimize therapeutic IA protocols and, lastly, to investigate further therapeutic principles, for example, T-cell reactivity to MBP before and after IA.
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